Discovery of a Pan-Melanocortin Receptor Antagonist [Ac-DPhe(pI)-Arg-Nal(2')-Orn-NH2] at the MC1R, MC3R, MC4R, and MC5R that Mediates an Increased Feeding Response in Mice and a 40-Fold Selective MC1R Antagonist [Ac-DPhe(pI)-DArg-Nal(2')-Arg-NH2].

Discovery of pan-antagonist ligands for the melanocortin receptors will help identify the physiological activities controlled by these receptors. The previously reported MC3R/MC4R antagonist Ac-DPhe(pI)-Arg-Nal(2')-Arg-NH2 was identified herein, for the first time, to possess MC1R and MC5R antagonist activity. Further structure-activity relationship studies probing the second and fourth positions were performed toward the goal of identifying potent melanocortin antagonists. Of the 21 tetrapeptides synthesized, 13 possessed MC1R, MC3R, MC4R, and MC5R antagonist activity. Three tetrapeptides were more than 10-fold selective for the mMC1R, including 8 (LTT1-44, Ac-DPhe(pI)-DArg-Nal(2')-Arg-NH2) that possessed 80 nM mMC1R antagonist potency and was at least 40-fold selective over the mMC3R, mMC4R, and mMC5R. Nine tetrapeptides were selective for the mMC4R, including 14 [SSM1-8, Ac-DPhe(pI)-Arg-Nal(2')-Orn-NH2] with an mMC4R antagonist potency of 1.6 nM. This compound was administered IT into mice, resulting in a dose-dependent increase in the food intake and demonstrating the in vivo utility of this compound series.

[1]  Jeonifer M. Garren,et al.  Discovery of the Potent and Selective MC4R Antagonist PF-07258669 for the Potential Treatment of Appetite Loss. , 2023, Journal of medicinal chemistry.

[2]  Mark D. Ericson,et al.  Incorporation of Indoylated Phenylalanine Yields a Sub-Micromolar Selective Melanocortin-4 Receptor Antagonist Tetrapeptide , 2022, ACS omega.

[3]  P. Grieco,et al.  Demonstration of a Common DPhe7 to DNal(2′)7 Peptide Ligand Antagonist Switch for Melanocortin-3 and Melanocortin-4 Receptors Identifies the Systematic Mischaracterization of the Pharmacological Properties of Melanocortin Peptides , 2022, Journal of medicinal chemistry.

[4]  Radleigh G. Santos,et al.  Functional Mixture-Based Positional Scan Identifies a Library of Antagonist Tetrapeptide Sequences (LAtTeS) with Nanomolar Potency for the Melanocortin-4 Receptor and Equipotent with the Endogenous AGRP(86-132) Antagonist. , 2021, Journal of medicinal chemistry.

[5]  Tingjun Hou,et al.  Structural insights into ligand recognition and activation of the melanocortin-4 receptor , 2021, Cell Research.

[6]  B. Kobilka,et al.  Structures of active melanocortin-4 receptor–Gs-protein complexes with NDP-α-MSH and setmelanotide , 2021, Cell Research.

[7]  Y. Peleg,et al.  Structure reveals the activation mechanism of the MC4 receptor to initiate satiation signaling , 2021, Science.

[8]  Mark D. Ericson,et al.  Discovery of Molecular Interactions of the Human Melanocortin-4 Receptor (hMC4R) Asp189 (D189) Amino Acid with the Endogenous G-Protein-Coupled Receptor (GPCR) Antagonist Agouti-Related Protein (AGRP) Provides Insights to AGRP's Inverse Agonist Pharmacology at the hMC4R. , 2021, ACS chemical neuroscience.

[9]  Mark D. Ericson,et al.  Comparative intracerebroventricular (ICV) and intrathecal (IT) administration of a nanomolar macrocyclic melanocortin receptor agonist MDE6-5-2c (c[Pro-His-DPhe-Arg-Trp-Dap-Ala-DPro]) decreases food intake in mice. , 2020, ACS chemical neuroscience.

[10]  Y. Boo,et al.  The First Human Clinical Trial on the Skin Depigmentation Efficacy of Glycinamide Hydrochloride , 2020, Biomedicines.

[11]  R. Stevens,et al.  Determination of the melanocortin-4 receptor structure identifies Ca2+ as a cofactor for ligand binding , 2020, Science.

[12]  I. Pogozheva,et al.  Incorporation of Agouti-Related Protein (AgRP) Human Single Nucleotide Polymorphisms (SNPs) in the AGRP-Derived Macrocyclic Scaffold c[Pro-Arg-Phe-Phe-Asn-Ala-Phe-DPro] Decreases Melanocortin-4 Receptor Antagonist Potency and Results in the Discovery of Melanocortin-5 Receptor Antagonists. , 2019, Journal of medicinal chemistry.

[13]  Y. Boo,et al.  Identification of small peptides and glycinamide that inhibit melanin synthesis using a positional scanning synthetic peptide combinatorial library , 2019, The British journal of dermatology.

[14]  R. Speth,et al.  Developing a Biased Unmatched Bivalent Ligand (BUmBL) Design Strategy to Target the GPCR Homodimer Allosteric Signaling (cAMP over β-Arrestin 2 Recruitment) Within the Melanocortin Receptors. , 2019, Journal of medicinal chemistry.

[15]  Mark D. Ericson,et al.  Synergistic Multiresidue Substitutions of a Macrocyclic c[Pro-Arg-Phe-Phe-Asn-Ala-Phe-dPro] Agouti-Related Protein (AGRP) Scaffold Yield Potent and >600-Fold MC4R versus MC3R Selective Melanocortin Receptor Antagonists. , 2018, Journal of medicinal chemistry.

[16]  Mark D. Ericson,et al.  Structure-Activity Relationship Studies of a Macrocyclic AGRP-Mimetic Scaffold c[Pro-Arg-Phe-Phe-Asn-Ala-Phe-DPro] Yield Potent and Selective Melanocortin-4 Receptor Antagonists and Melanocortin-5 Receptor Inverse Agonists That Increase Food Intake in Mice. , 2018, ACS chemical neuroscience.

[17]  M. M. Lunzer,et al.  Comparative in Vivo Investigation of Intrathecal and Intracerebroventricular Administration with Melanocortin Ligands MTII and AGRP into Mice. , 2017, ACS chemical neuroscience.

[18]  Mark D. Ericson,et al.  Structure-Activity Relationship Studies on a Macrocyclic Agouti-Related Protein (AGRP) Scaffold Reveal Agouti Signaling Protein (ASP) Residue Substitutions Maintain Melanocortin-4 Receptor Antagonist Potency and Result in Inverse Agonist Pharmacology at the Melanocortin-5 Receptor. , 2017, Journal of medicinal chemistry.

[19]  S. Luquet,et al.  α-Melanocyte stimulating hormone promotes muscle glucose uptake via melanocortin 5 receptors , 2016, Molecular metabolism.

[20]  Cody J Lensing,et al.  Ac-Trp-DPhe(p-I)-Arg-Trp-NH2, a 250-Fold Selective Melanocortin-4 Receptor (MC4R) Antagonist over the Melanocortin-3 Receptor (MC3R), Affects Energy Homeostasis in Male and Female Mice Differently. , 2016, ACS chemical neuroscience.

[21]  R. Speth,et al.  An in Vitro and in Vivo Investigation of Bivalent Ligands That Display Preferential Binding and Functional Activity for Different Melanocortin Receptor Homodimers. , 2016, Journal of medicinal chemistry.

[22]  Sathya M. Schnell,et al.  Microwave-assisted solid-phase synthesis of side-chain to side-chain lactam-bridge cyclic peptides. , 2015, Bioorganic & medicinal chemistry letters.

[23]  Mark D. Ericson,et al.  A fragment of the Escherichia coli ClpB heat-shock protein is a micromolar melanocortin 1 receptor agonist. , 2015, Bioorganic & medicinal chemistry letters.

[24]  Mark D. Ericson,et al.  Discovery of a β-Hairpin Octapeptide, c[Pro-Arg-Phe-Phe-Dap-Ala-Phe-DPro], Mimetic of Agouti-Related Protein(87-132) [AGRP(87-132)] with Equipotent Mouse Melanocortin-4 Receptor (mMC4R) Antagonist Pharmacology. , 2015, Journal of medicinal chemistry.

[25]  K. Freeman,et al.  Synthesis and Pharmacology of α/β(3)-Peptides Based on the Melanocortin Agonist Ac-His-dPhe-Arg-Trp-NH2 Sequence. , 2015, ACS medicinal chemistry letters.

[26]  A. Pappas,et al.  Melanocortin-5 receptor and sebogenesis. , 2011, European journal of pharmacology.

[27]  S. Woods,et al.  Assessment of feeding behavior in laboratory mice. , 2010, Cell metabolism.

[28]  V. Hruby,et al.  Design, synthesis, and biological activities of a potent and selective α‐melanotropin antagonist , 2009 .

[29]  E. Novellino,et al.  Design and microwave-assisted synthesis of novel macrocyclic peptides active at melanocortin receptors: discovery of potent and selective hMC5R receptor antagonists. , 2008, Journal of medicinal chemistry.

[30]  Xiaorong Zhu,et al.  Agouti-related protein is posttranslationally cleaved by proprotein convertase 1 to generate agouti-related protein (AGRP)83-132: interaction between AGRP83-132 and melanocortin receptors cannot be influenced by syndecan-3. , 2006, Endocrinology.

[31]  V. Hruby,et al.  Development of cyclic gamma-MSH analogues with selective hMC3R agonist and hMC3R/hMC5R antagonist activities. , 2006, Journal of medicinal chemistry.

[32]  G. Barsh,et al.  Structures of the agouti signaling protein. , 2005, Journal of molecular biology.

[33]  B. Gilchrest,et al.  Bone morphogenetic protein (BMP) signaling controls hair pigmentation by means of cross-talk with the melanocortin receptor-1 pathway. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[34]  Elissa J. Chesler,et al.  The melanocortin-1 receptor gene mediates female-specific mechanisms of analgesia in mice and humans , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[35]  W. Sadee,et al.  Design of novel chimeric melanotropin-deltorphin analogues. Discovery of the first potent human melanocortin 1 receptor antagonist. , 2003, Journal of medicinal chemistry.

[36]  K. Georgeson,et al.  Molecular Determinants of Human Melanocortin-4 Receptor Responsible for Antagonist SHU9119 Selective Activity* , 2002, The Journal of Biological Chemistry.

[37]  G. Barsh,et al.  Design, pharmacology, and NMR structure of a minimized cystine knot with agouti-related protein activity. , 2002, Biochemistry.

[38]  N. Richards,et al.  Novel agouti-related-protein-based melanocortin-1 receptor antagonist. , 2001, Journal of medicinal chemistry.

[39]  M. Bednarek,et al.  Selective, high affinity peptide antagonists of alpha-melanotropin action at human melanocortin receptor 4: their synthesis and biological evaluation in vitro. , 2001, Journal of medicinal chemistry.

[40]  Stanley J. Watson,et al.  A biochemical function for attractin in agouti-induced pigmentation and obesity , 2001, Nature Genetics.

[41]  R. Cone,et al.  A Unique Metalolic Sysdrone Causes Obesity in the Melanocortin-3 Receptor-Deficient Mouse. , 2000, Endocrinology.

[42]  Yue Feng,et al.  Inactivation of the mouse melanocortin-3 receptor results in increased fat mass and reduced lean body mass , 2000, Nature Genetics.

[43]  R. Cone,et al.  Structure activity studies of the melanocortin antagonist SHU9119 modified at the 6, 7, 8, and 9 positions☆ , 2000, Peptides.

[44]  G. Barsh,et al.  Down-regulation of Melanocortin Receptor Signaling Mediated by the Amino Terminus of Agouti Protein in XenopusMelanophores* , 1999, The Journal of Biological Chemistry.

[45]  M. Tota,et al.  Molecular interaction of Agouti protein and Agouti-related protein with human melanocortin receptors. , 1999, Biochemistry.

[46]  J. Wikberg,et al.  Discovery of a novel superpotent and selective melanocortin-4 receptor antagonist (HS024): evaluation in vitro and in vivo. , 1998, Endocrinology.

[47]  G. Barsh,et al.  Interaction of Agouti protein with the melanocortin 1 receptor in vitro and in vivo. , 1998, Genes & development.

[48]  W. Wilkison,et al.  Melanocortin receptor binding determinants in the agouti protein. , 1998, Biochemistry.

[49]  G. Barsh,et al.  Antagonism of central melanocortin receptors in vitro and in vivo by agouti-related protein. , 1997, Science.

[50]  M. Tota,et al.  ART (protein product of agouti-related transcript) as an antagonist of MC-3 and MC-4 receptors. , 1997, Biochemical and biophysical research communications.

[51]  J. Shutter,et al.  Hypothalamic expression of ART, a novel gene related to agouti, is up-regulated in obese and diabetic mutant mice. , 1997, Genes & development.

[52]  G. Barsh,et al.  Effects of recombinant agouti-signaling protein on melanocortin action. , 1997, Molecular endocrinology.

[53]  H. Schild pA, A NEW SCALE FOR THE MEASUREMENT OF DRUG ANTAGONISM , 1997, British journal of pharmacology and chemotherapy.

[54]  R. Cone,et al.  Targeted Disruption of the Melanocortin-4 Receptor Results in Obesity in Mice , 1997, Cell.

[55]  Victor J. Hruby,et al.  Role of melanocortinergic neurons in feeding and the agouti obesity syndrome , 1997, Nature.

[56]  J. Wikberg,et al.  Major pharmacological distinction of the ACTH receptor from other melanocortin receptors. , 1996, Life sciences.

[57]  R. Cone,et al.  Cyclic lactam alpha-melanotropin analogues of Ac-Nle4-cyclo[Asp5, D-Phe7,Lys10] alpha-melanocyte-stimulating hormone-(4-10)-NH2 with bulky aromatic amino acids at position 7 show high antagonist potency and selectivity at specific melanocortin receptors. , 1995, Journal of medicinal chemistry.

[58]  M. Lerner,et al.  Discovery and structure-function analysis of alpha-melanocyte-stimulating hormone antagonists. , 1994, The Journal of biological chemistry.

[59]  Richard P. Woychik,et al.  Agouti protein is an antagonist of the melanocyte-stimulating-hormone receptor , 1994, Nature.

[60]  M. Mortrud,et al.  Identification of a receptor for gamma melanotropin and other proopiomelanocortin peptides in the hypothalamus and limbic system. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[61]  S. Watson,et al.  Molecular cloning, expression, and gene localization of a fourth melanocortin receptor. , 1993, The Journal of biological chemistry.

[62]  L. Stubbs,et al.  The embryonic lethality of homozygous lethal yellow mice (Ay/Ay) is associated with the disruption of a novel RNA-binding protein. , 1993, Genes & development.

[63]  S. Watson,et al.  Molecular cloning of a novel melanocortin receptor. , 1993, The Journal of biological chemistry.

[64]  R. Woychik,et al.  Molecular characterization of the mouse agouti locus , 1992, Cell.

[65]  J. Wikberg,et al.  Molecular cloning and expression of the human melanocyte stimulating hormone receptor cDNA , 1992, FEBS letters.

[66]  M. Mortrud,et al.  The cloning of a family of genes that encode the melanocortin receptors. , 1992, Science.

[67]  G. Wilcox,et al.  Intrathecal morphine in mice: a new technique. , 1980, European journal of pharmacology.

[68]  G. Han,et al.  9-Fluorenylmethoxycarbonyl amino-protecting group , 1972 .

[69]  G. Han,et al.  9-Fluorenylmethoxycarbonyl function, a new base-sensitive amino-protecting group , 1970 .

[70]  E. Kaiser,et al.  Color test for detection of free terminal amino groups in the solid-phase synthesis of peptides. , 1970, Analytical biochemistry.